Karzinoid-Syndrom

 
Sonderbericht
Mit freundlicher Unterstützung der IPSEN Pharma GmbH, Ettlingen
 

Literatur

1. Rorstad O, J Surg Oncol 2005, 89(3):151–160
2. Zuetenhorst J, Taal B, Oncologist 2005, 10(2):123–131
3. Kulke M et al., J Clin Oncol 2017, 35(1):14–23
4. Anthony L et al., Poster, Abstract C1, NANETS 2015
5. Aggarwal G et al., Cleve Clin J Med 2008, 75(12):849–855
6. Yao J et al., J Clin Oncol 2008, 26:3063–3072
7. Pasieka J et al., Can J Surg 2001, 44(1):25–32
8. Modlin I et al., Lancet Oncol 2008, 9(1):61–72
9. Öberg K, Ann Oncol 2010, 21 (Suppl 7): vii72–vii80
10. Vinik A et al., Pancreas 2010, 39:713–34
11. DeVita V et al., eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams amp; Wilkins; 2000
12. Mamikunian G et al., eds. Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. 4th ed. Inglewood, CA: Inter Science Institute; 2009
13. Kvols L et al., N Engl J Med 1986, 315(11):663–666
14. Beaumont J et al., Pancreas 2012, 41(3):461–466
15. Goldstein G et al., Poster B6, American Society of Clinical Oncology, USA, März 2017
16. Fachinformation Somatuline Autogel®, Stand: Mai 2017
17. Fachinformation Xermelo®, Stand: September 2017
18. Pavel M et al., Neuroendocrinology 2016, 103(2):172–185
19. Pavel M et al., NANETS 2016, Abstract C8
20. Fauci A et al., In: Harrison's Principles of Internal Medicine Online. 17th ed. New York, NY: McGraw-Hill, Inc; 1997
21. Hutcheson J et al., Pharmacol Ther 2011, 132(2):146–157